EP0814830A1 - Lymphoblastoid natural interferon alpha production - Google Patents
Lymphoblastoid natural interferon alpha productionInfo
- Publication number
- EP0814830A1 EP0814830A1 EP96908839A EP96908839A EP0814830A1 EP 0814830 A1 EP0814830 A1 EP 0814830A1 EP 96908839 A EP96908839 A EP 96908839A EP 96908839 A EP96908839 A EP 96908839A EP 0814830 A1 EP0814830 A1 EP 0814830A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- interferon
- lymphoblastoid
- extract
- cells
- cell culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000011488 interferon-alpha production Effects 0.000 title description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract description 23
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract description 23
- 241000282414 Homo sapiens Species 0.000 claims abstract description 22
- 238000004113 cell culture Methods 0.000 claims abstract description 20
- 210000001541 thymus gland Anatomy 0.000 claims abstract description 20
- 230000001605 fetal effect Effects 0.000 claims abstract description 18
- 102000014150 Interferons Human genes 0.000 claims description 42
- 108010050904 Interferons Proteins 0.000 claims description 42
- 229940079322 interferon Drugs 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 241000711408 Murine respirovirus Species 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 32
- 239000002609 medium Substances 0.000 description 11
- 229940047124 interferons Drugs 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 3
- 229940116357 potassium thiocyanate Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Definitions
- Interferon Bac ground of the Invention Interferon is found in many vertebrates and seems to be one of the body's main lines of non-specific defense against viral infection. Interferon is a term generically comprehending a group of vertebrate glycoproteins and proteins which are known to have various biological activities, such as antiviral, antiproliferative and immunomodulatory activity. Interferons are all polypeptides consisting of approximately 150 amino acid residues, and has proved tentative successes with its use against hepatitis, herpes simplex, the common cold and even warts. However, one problem with interferon is the burdensome cost which has resulted from the difficulty of getting significant quantities of human interferon by conventional methods.
- Interferons have generally been named in terms of the species of animal cells producing the substance (e.g., human, murine, bovine, etc.), the type of cell involved (e.g., leukocyte, lymphoblastoid, fibroblast) and, occasionally, the type of inducing material responsible for the interferon production (e.g. , virus, immune). Interferon has been loosely classified by some researchers according to the induction mode as either Type I or Type II, with the former classification comprehending viral and nucleic acid induced interferon, and the latter class including the material produced as a lymphokine through induction by antigens and mitogens.
- interferons More recently, an orderly nomenclature system for interferon has been devised which classifies interferons into types on the basis of antigenic specificities. Under this newer classification system, the designations alpha, beta and gamma have been used to correspond to previous designations of leukocyte, fibroblast and Type II (immune) interferons, respectively.
- Alpha and beta interferons are usually acid-stable and correspond to what have been called Type I interferons.
- Gamma interferons are usually acid-labile and correspond to what have been called Type II interferons.
- interferon for the treatment of disease in man and animals has been the subject of intense research efforts in many laboratories, both in industry and in educational institutions around the world. In some of the earliest research activities interferon was shown to have antiviral properties and the most successful clinical therapeutical applications to date have been in the treatment of virus-related disease states. More recently it has been found that exogenous interferon is effective for the regression or remission of some metastatic disease states. The literature is replete with reports of research and development efforts directed to defining activities and potential therapeutic uses of interferon. Most of the reports described activities of interferon in vitro or its effects in vivo following parenteral, particularly intramuscular and intradermal administration. There have been some reports of successful topical and intranasal usages.
- An object of the present invention is to provide a compound which can be used for maintaining a differentiated cell line, specifically, of lymphoblastoid cells capable of producing natural human interferon- alpha.
- This invention relates to a novel compound and its method of use to maintain a differentiated, responsive lymphoblastoid cell line.
- the novel compound is an extract of human fetal thymus.
- the T- lymphocytes are the source of interferon alpha.
- Lymphoblastoid cells are the "cradle cells" for T- lymphocytes, which are one of the many existing forms of leukocytes. The lymphoblastoid cells are responsible for the interferon alpha endowment of the T- lymphocytes.
- the production in general, is based on a method originally devised by Cantell in Finland. Essentially his technique consists in making the leukocytes yield their interferon contents by stimulating them with the otherwise innocuous Sendai virus.
- researchers have been addressing the perspective of growing lymphoblastoid cell cultures in an ideal auxostatic medium with a sterile laboratory environment and subject these to Cantell's method in order to incite them to issue interferon alpha rather than isolating interferon alpha from donated which blood cells.
- lymphoblastoid cells After a few generations, the lymphoblastoid cells began to lose their differentiation and, once their morphological change was complete, they did not react at all to any stimulus. All the attempts of hampering the loss of cellular differentiation failed. Many methods were tried, from enzyme or chemical influences to rhythmic changes of the medium, without success.
- the method presented in this invention consists in the addition of a complex of natural substances to the auxostatic medium that contains the lymphoblastoid cell culture to maintain its differentiated state.
- this substance is an extract made of human fetal thymuses.
- Human fetal cells are used rather than established human adult cells to allow for a much more vigorous mitosis rate and substantially more economic interferon production.
- the lymphoblatoid cells do not lose their differentiation, but remain receptive to the stimulation by the Cantell method.
- these cultures do yield unrestricted volumes of natural interferon alpha that is completely independent of donors. Such production is perfectly predictable, whose volume is only limited by the available space and technological equipment.
- interferon has been accepted by an international committee assembled to devise a system for the orderly nomenclature of interferons: to qualify as an interferon, a factor must be a protein which exerts non ⁇ specific, antiviral activity at least in homologous cells through cellular metabolic process involving synthesis of both RNA and protein. "Interferon" as used herein in describing the present invention shall be deemed to have that definition and shall contemplate proteins, including glycoproteins, regardless of their cell source.
- the interferon can be derived from human or animal cell culture, and in accordance with the preferred embodiments is alpha or beta interferon. Proteins having activities similar to natural occurring interferons but with modified amino acid sequences are also contemplated as useful in accordance with this invention.
- the clinical agents of choice for use in the present invention are human leukocyte interferon and lymphoblastoid interferon, mass produced by procedures involving lymphoblastoid cell cultures, induction of interferon production, via Cantell's method and isolation of interferon from culture media.
- the fetal thymuses extract is added to the lymphoblastoid cell cultures.
- the source material is supplied after careful clinical screening of the thymus donors.
- the thymus cells are extracted under surgical sterility regime, then flashfrozen, and ground up to a 00 level, frozen powder, in a special grinder capable of operating at extremely low temperatures.
- the powder is then extended on large flat containers in a one millimeter layer and thawed out at room temperature under a vacuum. After the thawing, the dehydrated cells are exposed to an acid gas flow which breaks down their membranes. Then, the open lymphoblastoid (thymus) cells are subjected to ultracentrification with the purpose of separating the DNA contained in their cell nucleuses.
- the thus obtained substance is then diluted in a physiological, sterile saline solution and added to the auxostatic medium that contains and nourishes the lymphoblastoid cell culture growing in that medium.
- the extract made of human fetal thymuses is added to the adult lymphoblastoid cell culture at a rate of 2 milliliters per
- the cells can successfully be used subsequently in the Cantell interferon isolation process.
- the cells are immortal and continue mitotic divisions as long as the aforementioned fetal thymus extract is added.
- Human alpha-interferon can be prepared through the following procedures, commonly referred to as the Cantell procedure. The process begins with packs of human leukocytes. The buffy coats in these packs are pooled into centrifuge bottles, and then are diluted with 0.83% ammonium chloride. The mixture is incubated for 15 minutes with intermittent shaking, and is then centrifuged for 20 minutes at 2000 rp . The supernatant is discarded, and the cell pellets are resuspended with a minimal volume of sterile pharmaceutical grade arabic gum (C 5 H 10 O 5 ). The mixture is then diluted with ammonium chloride and centrifuged.
- the supernatant is again discarded, and the remaining cell pellets are resuspended with a minimal volume of a tissue culture medium such as Minimal Essential Medium (MEM), available from KC Biological.
- MEM Minimal Essential Medium
- the cell concentration is determined with a Coulter counter. Interferon induction takes place in glass or plastic bottles.
- the induction medium contains MEM, 75mM Hepes (available from Calbiochem), 75mM Tricine (available from Sigma Chemical Co.), human gamma serum (18mg/ml), and gentamycin sulfate (from M. A. Bioproducts; 50mcg/ml).
- the cells are added to the induction vessels at a final concentration of about 5 to 10 million cells per milliliter.
- the induction vessel is incubated in a 37 degree(s) C. water bath, and alpha-interferon is added as a primer. After two hours, Sendai virus is added to the induction mixture. This causes alpha interferon to be produced in the supernatant by the leukocytes. After a 12- 18 hour incubation time, the induction mixture is centrifuged. The cells are discarded, and the supernatant is then purified. The crude interferon is chilled to 10 degree(s) C. or below in an ice bath. Five molar potassium thiocyanate is added to obtain a final concentration of 0.5M. This solution is stirred for 15 minutes, and then its pH is lowered to 3.3 by adding hydrochloric acid. The mixture is then centrifuged at 2800 rpm for 30 minutes, and the supernatant is discarded.
- the pellets are then resuspended in 95% ethanol and are stirred for 15 minutes. This suspension is centrifuged at 2800 rpm for 20 minutes, and the pellets are discarded. The mixture is stirred for 10 minutes, and then centrifuged at 280 rpm for 20 minutes. The pellets are discarded. The pH of the supernatant is then adjusted to 8 with sodium hydroxide. This solution is stirred for 10 minutes, followed by centrifugation at 2800 rpm for 20 minutes. The supernatant is discarded, and the pellets are resuspended with 0.5M potassium thiocyanate in a 0.1M sodium phosphate buffer. This suspension is stirred at 4 degree(s) C.
- the suspension is centrifuged at 2800 rpm for 20 minutes, and the pellets are discarded.
- the pH of the supernatant is adjusted to 5.3 with hydrochloric acid.
- the pH of the supernatant is adjusted to 2.8 with hydrochloric acid, followed by further stirring for 20 minutes. This mixture is centrifuged at 2800 rpm, and the resulting pellet is purified human alpha- interferon.
- Interferon Preparations are commercially available from Hoffmann-LaRoche, Burroughs-Wellcome and Schering- Plough.
- the fetal thymus extract could be used with these methods as well.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US404667 | 1989-09-07 | ||
US40466795A | 1995-03-15 | 1995-03-15 | |
PCT/US1996/003613 WO1996028184A1 (en) | 1995-03-15 | 1996-03-15 | Lymphoblastoid natural interferon alpha production |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0814830A1 true EP0814830A1 (en) | 1998-01-07 |
EP0814830A4 EP0814830A4 (en) | 2001-12-12 |
Family
ID=23600547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96908839A Withdrawn EP0814830A4 (en) | 1995-03-15 | 1996-03-15 | Lymphoblastoid natural interferon alpha production |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0814830A4 (en) |
CN (1) | CN1148342A (en) |
AU (1) | AU5254596A (en) |
WO (1) | WO1996028184A1 (en) |
-
1996
- 1996-03-15 EP EP96908839A patent/EP0814830A4/en not_active Withdrawn
- 1996-03-15 AU AU52545/96A patent/AU5254596A/en not_active Abandoned
- 1996-03-15 CN CN96190195.0A patent/CN1148342A/en active Pending
- 1996-03-15 WO PCT/US1996/003613 patent/WO1996028184A1/en not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO9628184A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1148342A (en) | 1997-04-23 |
AU5254596A (en) | 1996-10-02 |
WO1996028184A1 (en) | 1996-09-19 |
EP0814830A4 (en) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chomyn | [29] Platelet-mediated transformation of human mitochondrial DNA-less cells | |
Galbraith et al. | Transferrin binding by human lymphoblastoid cell lines and other transformed cells | |
EP0302894B1 (en) | Method of culturing leukocytes | |
Giard et al. | Human interferon production with diploid fibroblast cells grown on microcarriers | |
US20120027678A1 (en) | Method of using stem cells to aid in diagnosis | |
EP0240348B1 (en) | Agent for the removal of nucleic acids and/or endotoxin and method for the removal thereof | |
Fernandez-Botran et al. | Methods in cellular immunology | |
Kitamura et al. | Differentiation and transdifferentiation of mast cells; a unique member of the hematopoietic cell family | |
CN1122716C (en) | Extracorporeal ceel culture and transplantation kits | |
KR860000898B1 (en) | Producing method of human chorionic gonadotpopin | |
JPS6154040B2 (en) | ||
US5759856A (en) | Cell culture system | |
EP0814830A1 (en) | Lymphoblastoid natural interferon alpha production | |
EP0254593A2 (en) | Preparation and uses of interferon-gamma | |
WO2023024215A1 (en) | Long-acting recombinant human interleukin-2 fusion protein, and preparation method therefor and application thereof | |
US4452893A (en) | Cell growth medium supplement | |
Wilt | The concept of messenger RNA and cytodifferentiation | |
JP2003511389A (en) | Regulated / unfolded ezrin peptide | |
US4124448A (en) | Process for the large scale production of human growth hormone by serial secondary suspension culture | |
KR970002165B1 (en) | Preparation and uses of ñò-interferon | |
KR860000896B1 (en) | Producing method of human prolactin | |
Chang et al. | Spontaneous Cytotoxicity by Monocyte‐Enriched Subpopulations of Human Peripheral Blood Mononuclear Cells against Human or Mouse Anchorage‐Dependent Tumour Cell Lines: Contribution of NK‐like Cells | |
US7521234B2 (en) | Mammalian immortalized liver cell | |
SU745948A1 (en) | Sheep embryo fibroblast (sef) entwine cell line strain as ox leucose virus (olv) producent | |
JP2566761B2 (en) | Bone marrow monocytic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971009 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20011026 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010401 |